Herpes Virus Therapy of Prostate Cancer
Abstract
The development of replication-competent viral vectors has offered a distinct advantage for prostate cancer gene therapy because of viral multiplication and spread within the tumor. G207, a second generation, multi-mutated HSV-1 vector has been shown to be very effective against human prostate cancer cell lines in vitro and in vivo following both direct intraneoplastic inoculation as well as following systemic intravenous inoculation. Moreover this efficacy applies to both androgen-sensitive as well as androgen-insensitive tumors and for post-irradiation recurrences. We now demonstrate that in a rodent prostate cancer model, NV1023 was more effective against Tramp tumors than either G207 or G47 delta, a G207 derivative. Following intraneoplastic therapy, the survival of NV1023 treated mice was extended by 5 weeks as compared to mock mice. Moreover in a bilateral tumor model , the virus treated (left) tumor volume was reduced to approximately one third the size of mock tumors. The untreated (right) tumors also regressed as expected with the tumor volume reduced to half the size of mock tumors. We have completed our studies of G207 toxicity following intraprostatic inoculation in animal models and demonstrated that G207 can be safely inoculated into the prostate. We have also demonstrated that sequential rather than simultaneous irradiation may be as beneficial for vectors such as G207 in treating prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2001
- Accession Number
- ADA402401
Entities
People
- Robert L. Martuza
Organizations
- Massachusetts General Hospital